Quantcast
Are you getting the best rate from your broker?
Compare your broker's rates now to find out if you can save money

Choose your broker below
Thank you for selecting your broker
We are redirecting you to the Broker Center now
Welcome to Dividend.com. Please help us personalize your experience.

Select the one that best describes you
Thank you for your submission, we hope you enjoy your experience
ALERT

‘Trump Bump’ Forces out MedTech Company from Best Dividend Stocks List

Dividend logo

When investors think of biotech stocks, the word “lottery” comes to mind. And for the most part, they are right. The vast bulk of the sector made up of smaller, early-stage drug developers with only one, or maybe two, new therapies in development. These firms live or die by how one drug performs. Fail the first round of a clinical trial and the stock is done for. Make it past the FDA’s watch and the stock soars.

A “lottery ticket” is certainly an accurate comparison when it comes to investing in biotech.

To read the Full Story, Go Premium or Log In

Popular Articles

Premium Presidentdonaldtrump
News

Market Wrap for January 20: Where’s That ‘Trump Bump’ Again?

It’s finally here, the inauguration of President Trump. With the event and the transition of...

News

Trending: Dividend Heavyweights Highlight Risk Aversion During Inauguration Week

Dividend.com analyzes the search patterns of our visitors each week. By sharing these trends with...

Rising Interest Rates

As Fed Hikes Rates, History Offers a Glimpse of Where Wall Street Is Headed

The stock market over the next few years may look markedly different than over the last few...